fda approval status of bpc-157 Exciting news for peptides coming out today's committee hearing! The Pharmacy Compounding Advisory Committee voted 8-6 to recommend adding BPC- 157 to the 503A Bulks List for use in compounding for FDA Meeting Approves Peptides: BPC-157

Possible side effects can include stomach upset, nerve damage, and skin conditions

doi:10.1590/1516-3180.2015.01382111

Comparison CompoundClassPathway / targetResearch focusFormat 5-Amino-1MQSmall moleculeNNMT inhibitionNAD / SAM metabolismVial 5-Amino-1MQ CapsulesSmall moleculeNNMT inhibitionNAD / SAM metabolismCapsules SLU-PP-332Small moleculePan-ERR agonismMitochondrial gene expressionVial SLU-PP-332 CapsulesSmall moleculePan-ERR agonismMitochondrial gene expressionCapsules Tesofensine CapsulesSmall moleculeMonoamine reuptakeCNS / monoaminergic signallingCapsules Enclomiphene CapsulesSmall moleculeEstrogen receptor (SERM)HPG-axis signallingCapsules AICARSmall moleculeAMPK activationCellular energy sensingVial AOD-9604Peptide fragmenthGH fragment (176-191) signallingLipolytic-pathway signallingVial AOD-9604 CapsulesPeptide fragmenthGH fragment (176-191) signallingLipolytic-pathway signallingCapsules GLP-3 (Reta)PeptideIncretin receptorMetabolic signalling researchVial Every compound in this category is supplied as Research Use Only material with: Peer-reviewed literature and mechanism background underpinning this category are maintained in the linked research articles below

Blood tests show equivalent B12 status whether supplementing with cyanocobalamin or methylcobalamin at equal doses